Bayer to review Roundup's future in U.S. after court setback
By Carl Surran SA News Editor May 26, 2021 10:49 PM ET
Bayer (OTCPK:BAYRY) says it will evaluate whether to continue using glyphosate in its Roundup weedkiller in the residential U.S. market after a judge today rejected its plan to settle future claims alleging the herbicide causes cancer.
Bayer also says it will abandon attempts at a court-approved solution to address its future Roundup liability, and instead will pursue options such as creating a new website with studies relevant to Roundup's safety that could also be reflected on its label.
The company says it will rethink selling glyphosate-based products to U.S. residential consumers - the source of the bulk of lawsuits - while continuing to sell to professional and agricultural users.
The U.S. Environmental Protection Agency has said Roundup is safe and would not permit a cancer warning label, but that leaves the company in a quandary over how to contain liability on a product it sells without any warning label.
Earlier this month, Bayer lost an appeal in one of the three Roundup cases to go to trial.
Now read: Bayer plunges on 'prolonged uncertainty' from Roundup settlement rejection
Note: There are active links contained within the original article linked below.